دورية أكاديمية
[Extracorporeal photopheresis in the treatment of patients with refractory chronic graft-versus-host disease after allogeneic bone marrow transplantation].
| العنوان: | [Extracorporeal photopheresis in the treatment of patients with refractory chronic graft-versus-host disease after allogeneic bone marrow transplantation]. |
|---|---|
| المؤلفون: | Bykova TA, Kozlov AV, Stancheva NV, Semënova EV, Kulagina II, Bondarenko SN, Vavilov VN, Morozova EV, Zubarovskaia LS, Afanas'ev BV |
| المصدر: | Terapevticheskii arkhiv [Ter Arkh] 2013; Vol. 85 (8), pp. 60-8. |
| نوع المنشور: | English Abstract; Journal Article |
| اللغة: | Russian |
| بيانات الدورية: | Publisher: ZAO 'Konsilium Medikum Country of Publication: Russia (Federation) NLM ID: 2984818R Publication Model: Print Cited Medium: Print ISSN: 0040-3660 (Print) Linking ISSN: 00403660 NLM ISO Abbreviation: Ter Arkh Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2018- > : Moskva : ZAO 'Konsilium Medikum' Original Publication: Moskva : Izdatelʹstvo Medit︠s︡ina |
| مواضيع طبية MeSH: | Bone Marrow Transplantation/*adverse effects , Graft vs Host Disease/*therapy , Hematopoietic Stem Cell Transplantation/*adverse effects , Photopheresis/*methods , Transplantation, Homologous/*adverse effects, Adolescent ; Adult ; Child ; Child, Preschool ; Chronic Disease ; Graft vs Host Disease/etiology ; Humans ; Middle Aged ; Photopheresis/adverse effects ; Survival Rate ; Treatment Outcome ; Young Adult |
| مستخلص: | Aim: To evaluate the efficiency of extracorporeal photopheresis (ECP) in the treatment of patients with refractory chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Subjects and Methods: The study included 49 patients aged 2 to 55 years. Allo-HSCT was carried out in 38 (79%) patients with acute leukemias, 5 (10%) with chronic leukemias, 4 (8%) with myelodysplastic syndrome/myeloproliferative disease, and 2 (3%) with other hematologic diseases. The patients included in the study had glucocorticosteroid (GCS)-refractory disseminated cGVHD or a history of severe complications from GCS therapy. Results: When evaluating the efficiency of therapy, its response was recorded in 37 (77%) cases; the best results were obtained in patients with hepatic (82%), mucosal (76%), and skin (74%) lesions. The mean severity according to the cGVHD Working Group, National Institutes of Health, and a platelet level of more than 100.10(9)/1 were defined as factors improving a therapy response. In the patients receiving ECP, the overall survival was 70%. The latter was higher in the group of patients who had responded to ECP therapy without involving the gastrointestinal tract in the cGVHD process and in those receiving a combination of ECP and other immunosuppressive drugs. Conclusion: ECP is an effective treatment for patients with refractory cGVHD, it may be used in those with a history of severe complications from GCS therapy. ECP allows the dose of GCS to be reduced to the point of complete discontinuation. |
| تواريخ الأحداث: | Date Created: 20131022 Date Completed: 20131101 Latest Revision: 20131021 |
| رمز التحديث: | 20240628 |
| PMID: | 24137966 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0040-3660 |
|---|